Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure.

Le Nouën C, McCarty T, Brown M, Smith ML, Lleras R, Dolan MA, Mehedi M, Yang L, Luongo C, Liang B, Munir S, DiNapoli JM, Mueller S, Wimmer E, Collins PL, Buchholz UJ.

Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E386-E395. doi: 10.1073/pnas.1619242114. Epub 2017 Jan 3.

2.

The Relationship of Clinical Nurses' Perceptions of Structural and Psychological Empowerment and Engagement on Their Unit.

DiNapoli JM, O'Flaherty D, Musil C, Clavelle JT, Fitzpatrick JJ.

J Nurs Adm. 2016 Feb;46(2):95-100. doi: 10.1097/NNA.0000000000000302.

PMID:
26796822
3.

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner.

Jeong KI, Piepenhagen PA, Kishko M, DiNapoli JM, Groppo RP, Zhang L, Almond J, Kleanthous H, Delagrave S, Parrington M.

PLoS One. 2015 Jun 24;10(6):e0130517. doi: 10.1371/journal.pone.0130517. eCollection 2015.

4.

Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization.

Le Nouën C, Brock LG, Luongo C, McCarty T, Yang L, Mehedi M, Wimmer E, Mueller S, Collins PL, Buchholz UJ, DiNapoli JM.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13169-74. doi: 10.1073/pnas.1411290111. Epub 2014 Aug 25.

5.

A theory-based computer mediated communication intervention to promote mental health and reduce high-risk behaviors in the LGBT population.

DiNapoli JM, Garcia-Dia MJ, Garcia-Ona L, O'Flaherty D, Siller J.

Appl Nurs Res. 2014 Feb;27(1):91-3. doi: 10.1016/j.apnr.2013.10.003. Epub 2013 Oct 28.

PMID:
24286722
6.

Concept analysis: resilience.

Garcia-Dia MJ, DiNapoli JM, Garcia-Ona L, Jakubowski R, O'Flaherty D.

Arch Psychiatr Nurs. 2013 Dec;27(6):264-70. doi: 10.1016/j.apnu.2013.07.003. Epub 2013 Sep 24. Review.

PMID:
24238005
7.

Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.

Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous H.

PLoS One. 2012;7(10):e46714. doi: 10.1371/journal.pone.0046714. Epub 2012 Oct 11.

8.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024. Epub 2010 Oct 27.

9.

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL.

Virology. 2010 Apr 10;399(2):290-8. doi: 10.1016/j.virol.2010.01.015. Epub 2010 Feb 2.

10.

Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity.

Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK.

J Virol. 2010 Mar;84(5):2408-20. doi: 10.1128/JVI.02135-09. Epub 2009 Dec 23.

11.

Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A.

J Virol. 2010 Feb;84(3):1489-503. doi: 10.1128/JVI.01946-09. Epub 2009 Nov 18.

12.

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A.

Vaccine. 2009 Mar 4;27(10):1530-9. doi: 10.1016/j.vaccine.2009.01.009. Epub 2009 Jan 23.

14.

Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

DiNapoli JM, Yang L, Suguitan A Jr, Elankumaran S, Dorward DW, Murphy BR, Samal SK, Collins PL, Bukreyev A.

J Virol. 2007 Nov;81(21):11560-8. Epub 2007 Aug 22.

15.

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.

DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A.

Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93. Epub 2007 May 29.

Supplemental Content

Loading ...
Support Center